This proposal seeks continuation of a successful training program in systemic autoimmunity at the Beth Israel Medical Deaconess Medical Center (BIDMC), Harvard Medical School (HMS). It requests support for three trainees each year to spend at least two years in the program. Trainees enter the program through one of the following tracks: Physicians who seek training in rheumatology or nephrology, physicians who enter other clinical fellowship programs including neurology and dermatology, physicians who have completed clinical training in a field relevant to systemic autoimmune diseases and PhDs with background in immunology, biochemistry and cell/molecular biology. The major criterion for selection is evidence of commitment to the study of systemic autoimmune diseases. Through this training physicians will develop skills in immunology and biology/biochemistry, whereas PhDs will become familiar with clinical issues pertinent to the study of systemic autoimmune diseases. Research activities will span studies in human and animal T cells, B cells, NKT cells, macrophages, mast cells, costimulation, immune cell signaling, immune tolerance, control of cytokine expression and function, pertinent aspects of regional immunology and biology (kidney, skin and nervous system), human genetics, immunodeficiency, complement and immunomodulation. The chief method of instruction involves personal involvement in a program of basic research under the close supervision of a faculty member. Moreover, a structured program of didactic courses in research seminars, journal clubs, research presentations in national and international meetings and grant writing is in place. The primary facilities for training are at BIDMC and HMS-affiliated institutions. The Program will be administered by the Program Director assisted by two senior experienced mentors, an administrator and three committees (Faculty, Internal and External Advisory) and evaluated through a rigorous process. Graduating trainees will be able to plan, seek funding and execute cutting edge research in systemic autoimmune diseases and will be properly tooled to develop new diagnostics and therapeutics.
This program develops top-notch researchers in the study of Systemic Autoimmune Diseases who will lead basic and Clinical research in academic centers to advance the care of people suffering from these diseases.
|Sekar, Aswin; Bialas, Allison R; de Rivera, Heather et al. (2016) Schizophrenia risk from complex variation of complement component 4. Nature 530:177-83|
|Kasper, Isaac R; Apostolidis, Sokratis A; Sharabi, Amir et al. (2016) Empowering Regulatory T Cells in Autoimmunity. Trends Mol Med 22:784-97|
|Suárez-Fueyo, Abel; Bradley, Sean J; Tsokos, George C (2016) T cells in Systemic Lupus Erythematosus. Curr Opin Immunol 43:32-38|
|Macosko, Evan Z; Basu, Anindita; Satija, Rahul et al. (2015) Highly Parallel Genome-wide Expression Profiling of Individual Cells Using Nanoliter Droplets. Cell 161:1202-1214|
|Bradley, Sean J; Suarez-Fueyo, Abel; Moss, David R et al. (2015) T Cell Transcriptomes Describe Patient Subtypes in Systemic Lupus Erythematosus. PLoS One 10:e0141171|
|Bove, Riley; Secor, Elizabeth; Chibnik, Lori B et al. (2014) Age at surgical menopause influences cognitive decline and Alzheimer pathology in older women. Neurology 82:222-9|
|Bove, Riley; Musallam, Alexander; Healy, Brian C et al. (2013) No sex-specific difference in disease trajectory in multiple sclerosis patients before and after age 50. BMC Neurol 13:73|
|Bove, Riley; Secor, Elizabeth; Healy, Brian C et al. (2013) Evaluation of an online platform for multiple sclerosis research: patient description, validation of severity scale, and exploration of BMI effects on disease course. PLoS One 8:e59707|
|Bove, Riley (2013) Autoimmune diseases and reproductive aging. Clin Immunol 149:251-64|
|Davis, Trevor E; Kis-Toth, Katalin; Szanto, Attila et al. (2013) Glucocorticoids suppress T cell function by up-regulating microRNA-98. Arthritis Rheum 65:1882-90|
Showing the most recent 10 out of 17 publications